Boston Scientific Corp (NYSE:BSX)
| 42.33 Delayed Data As of Aug 12 |  +0.57 / +1.36%Today’s Change | 34.98 Today|||52-Week Range 47.50 | -0.35% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $60.6B |
Company Description
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.
Contact Information
Boston Scientific Corp. 300 Boston Scientific Way Marlborough Massachusetts 01752-1234 |
Employees
Shareholders
| Mutual fund holders | 54.55% |
| Other institutional | 39.32% |
| Individual stakeholders | 1.45% |
Top Executives
| Michael F. Mahoney | Chairman, President & Chief Executive Officer |
| Edward F. Mackey | Executive Vice President-Global Operations |
| Daniel J. Brennan | Chief Financial Officer & Executive Vice President |
| Jodi Eddy | Senior VP, Chief Information & Digital Officer |
| Ian T. Meredith | Global Chief Medical Officer & Executive VP |
